Yan Chen

Yan Chen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
SWShengfeng Wang
Shengfeng Wang
QZQuanfeng Zhu
Quanfeng Zhu
CZChengcheng Zhang
Chengcheng Zhang
SHShuang Hu
Shuang Hu
DLDaqun Liu
Daqun Liu
GJGuojun Jiang
Guojun Jiang
Background: Aloe-emodin (AOE), the principal anthraquinone constituent derived from aloe and rhubarb, exhibits antioxidant and anti-inflammatory properties, suggesting its therapeutic potential against hyperuricemia (HUA) and associated renal injury. Here, we investigated the potential of AOE in mitigating HUA and related kidney damage, with a focus on its underlying biological mechanisms.Methods: A HUA mouse model was established by oral gavage of potassium oxonate (PO, 1.5 g/kg) and adenine (Ad, 0.1 g/kg). Serum uric acid (UA) levels, kidney function indicators, histological changes, inflammatory response, and oxidative stress state were assessed to evaluate the urate-lowering and kidney-protective roles of AOE. Furthermore, transcriptomic profiling and RT-qPCR analysis were employed to investigate how AOE contributes to UA reduction and renal protection.Results: AOE lowered serum UA levels and inhibited xanthine oxidase and adenosine deaminase activity. Moreover, AOE improved kidney function indicators (reflected by reductions in serum creatinine and blood urea nitrogen levels), restored the integrity of renal tissue structure, and mitigated inflammation and oxidative stress in HUA-exposed animals. Transcriptomic analysis revealed 2,307 differentially expressed key genes associated with AOE against HUA in kidney. Furthermore, AOE downregulated p65/RelA and NF-κB1/p50 transcript levels, while increasing PPARα, PPARγ, and CPT2 expression.Conclusion: AOE effectively lowered serum UA levels, and exhibited renal protection in the PO/Ad-induced HUA mouse model by dampening inflammatory signaling and restoring redox equilibrium, likely through the PPAR and NF-κB pathways. This study demonstrated that AOE is a promising natural candidate with a desirable safety profile for treating HUA and renal injury, and more experimental validation are needed in the future.

27 June 2025 in Advanced Science
Verified
Journal Article
Open access
ZSZe‐Yu Sun
Ze‐Yu Sun
JYJiayi Yuan
Jiayi Yuan
DJDivya Jaiswal
Divya Jaiswal
JGJingxuan Ge
Jingxuan Ge
TLTianjian Liang
Tianjian Liang
ZFZhiwei Feng
Zhiwei Feng
Antibodies are crucial for medical applications, yet traditional methods for designing sequences are inefficient. This study introduces AntiBMPNN, an advanced deep‐learning framework that leverages an antibody‐specific 3D dataset, a fine‐tuned message‐passing neural network (MPNN), a frequency‐based scoring function, and AlphaFold 3 to achieve highly accurate antibody sequence design. AntiBMPNN surpasses ProteinMPNN with a perplexity of 1.5 and over 80% sequence recovery. Its scoring function, combined with AlphaFold 3, effectively prioritizes sequences based on structural recovery, positional stability, and biochemical or complex properties. Experimental validation highlights a 75% success rate in single‐point antibody design. AntiBMPNN consistently outperforms AbMPNN, AntiFold, and ProteinMPNN in designing complementarity determining regions (CDR) 1‐3, yielding stronger binding affinities. For CDR1 of huJ3 (anti‐HIV nanobody), it achieves a half maximal effective concentration (EC₅₀) of 9.2 nM (nanomolar), better than ProteinMPNN (135.2 nM) and AntiFold (59.3 nM), and comparable to AbMPNN (6.6 nM). For CDR2 of the D6 nanobody (targeting CD16), AntiBMPNN reaches 0.3 nM, outperforming AbMPNN (2.3 nM), AntiFold (0.7 nM), and ProteinMPNN (0.7 nM). In CDR3 of huJ3, it achieves 1.7 nM, surpassing AbMPNN (51.2 nM), with no detectable activity from AntiFold or ProteinMPNN. These findings confirm that AntiBMPNN‐designed sequences for J3 and D6 outperform the originals, highlighting its potential to improve therapeutic antibody design.

17 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
JCJin Cheng
Jin Cheng
YHYixuan Hao
Yixuan Hao
QSQin Shi
Qin Shi
GHGuanyu Hou
Guanyu Hou
YWYanan Wang
Yanan Wang
GYGuanghua Yu
Guanghua Yu
The transmission and infectivity of COVID-19 have caused a pandemic that has lasted for several years. This is due to the constantly changing variants and subvariants that have evolved rapidly from SARS-CoV-2. To discover drugs with therapeutic potential for COVID-19, we focused on the 3CL protease (3CLpro) of SARS-CoV-2, which has been proven to be an important target for COVID-19 infection. Computational prediction techniques are quick and accurate enough to facilitate the discovery of drugs against the 3CLpro of SARS-CoV-2. In this paper, we used both ligand-based virtual screening and structure-based virtual screening to screen the traditional Chinese medicine small molecules that have the potential to target the 3CLpro of SARS-CoV-2. MD simulations were used to confirm these results for future in vitro testing. MCCS was then used to calculate the normalized free energy of each ligand and the residue energy contribution. As a result, we found ZINC15676170, ZINC09033700, and ZINC12530139 to be the most promising antiviral therapies against the 3CLpro of SARS-CoV-2.

10 March 2022 in Structural Chemistry
Verified
Journal Article
Closed access
PDF file
LZLinan Zhao
Linan Zhao
LFLe Fu
Le Fu
GLGuangping Li
Guangping Li
YSYan Shen
Yan Shen
YHYong Hu
Yong Hu
YWYuanqiang Wang
Yuanqiang Wang

20 January 2025 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
XWXinhai Wu
Xinhai Wu
CGChen‐Xin Guo
Chen‐Xin Guo
SWSheng‐Feng Wang
Sheng‐Feng Wang
TGTing‐Ting Gong
Ting‐Ting Gong
JYJing‐Wei Yao
Jing‐Wei Yao
YCYan Chen
Yan Chen

3 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JYJiayi Yuan
Jiayi Yuan
XXXiaowei Xu
Xiaowei Xu
ZSZe-Yu Sun
Ze-Yu Sun
TLTianjian Liang
Tianjian Liang
JGJingxuan Ge
Jingxuan Ge
ZFZHIWEI FENG
ZHIWEI FENG
MHC-II neoantigens play a critical role in immunotherapy, either as direct effectors or through their influence on CD8 + T cells. However, only a small fraction of tumor DNA mutations qualify as functional neoantigens, and current prediction tools often lack accuracy, leading to the low immunogenicity of predicted neoantigens in vivo. Here, we present EpiMII, a Graph Neural Network model for MHC-II epitope design, which learns from the structural features of epitopes to predict their sequences. To train EpiMII, we constructed a reliable, large dataset containing 142,934 MHC-II epitope structures. This approach achieves a 4.2x improvement over ProteinMPNN, with a sequence recovery rate of 78.0% for known MHC-II epitopes in the Protein Data Bank. As a case study, we designed a neoantigen from hepatocellular carcinoma. All five designed epitopes significantly activated CD4 + T cells in vitro and induced secretion of IFN-γ and TNF-α. Notably, one epitope treatment significantly reduced tumor volume in mice in vivo. EpiMII offers a novel and efficient approach for identifying MHC-II epitopes/neoantigens, potentially contributing to vaccine development.